Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 221

1.

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment.

Herukka SK, Hallikainen M, Soininen H, Pirttilä T.

Neurology. 2005 Apr 12;64(7):1294-7.

PMID:
15824371
2.

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

Riemenschneider M, Lautenschlager N, Wagenpfeil S, Diehl J, Drzezga A, Kurz A.

Arch Neurol. 2002 Nov;59(11):1729-34.

PMID:
12433260
3.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
4.
5.

CSF Abeta42, Tau and phosphorylated Tau, APOE epsilon4 allele and MCI type in progressive MCI.

Herukka SK, Helisalmi S, Hallikainen M, Tervo S, Soininen H, Pirttilä T.

Neurobiol Aging. 2007 Apr;28(4):507-14. Epub 2006 Mar 20.

PMID:
16546302
6.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
7.

Diagnosing prodromal Alzheimer's disease: role of CSF biochemical markers.

Parnetti L, Lanari A, Silvestrelli G, Saggese E, Reboldi P.

Mech Ageing Dev. 2006 Feb;127(2):129-32. Epub 2005 Nov 7.

PMID:
16274728
8.

Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).

Koopman K, Le Bastard N, Martin JJ, Nagels G, De Deyn PP, Engelborghs S.

Neurochem Int. 2009 Sep;55(4):214-8. doi: 10.1016/j.neuint.2009.02.017. Epub 2009 Mar 5.

PMID:
19524111
9.

Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, Blennow K.

Neurosci Lett. 1999 Sep 24;273(1):5-8.

PMID:
10505638
10.

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment.

Vanderstichele H, De Meyer G, Andreasen N, Kostanjevecki V, Wallin A, Olsson A, Blennow K, Vanmechelen E.

Clin Chem. 2005 Sep;51(9):1650-60. Epub 2005 Jul 14.

11.

Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults.

Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM.

Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.

PMID:
17210801
12.

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

Lewczuk P, Kornhuber J, Vanderstichele H, Vanmechelen E, Esselmann H, Bibl M, Wolf S, Otto M, Reulbach U, Kölsch H, Jessen F, Schröder J, Schönknecht P, Hampel H, Peters O, Weimer E, Perneczky R, Jahn H, Luckhaus C, Lamla U, Supprian T, Maler JM, Wiltfang J.

Neurobiol Aging. 2008 Jun;29(6):812-8. Epub 2007 Jan 19.

PMID:
17239996
13.

Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice.

Parnetti L, Lanari A, Saggese E, Spaccatini C, Gallai V.

Neurol Sci. 2003 Oct;24(3):199-200.

PMID:
14598086
14.

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

Hampel H, Teipel SJ, Fuchsberger T, Andreasen N, Wiltfang J, Otto M, Shen Y, Dodel R, Du Y, Farlow M, Möller HJ, Blennow K, Buerger K.

Mol Psychiatry. 2004 Jul;9(7):705-10.

PMID:
14699432
16.

Amyloid beta(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease.

Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, Van Swieten JC, Scheltens P.

Neurology. 2004 May 11;62(9):1580-4.

PMID:
15136685
17.

CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.

van der Vlies AE, Verwey NA, Bouwman FH, Blankenstein MA, Klein M, Scheltens P, van der Flier WM.

Neurology. 2009 Mar 24;72(12):1056-61. doi: 10.1212/01.wnl.0000345014.48839.71.

PMID:
19307538
18.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
19.

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.

Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.

J Int Neuropsychol Soc. 2008 Jul;14(4):582-90. doi: 10.1017/S135561770808079X.

PMID:
18577287
20.

Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.

Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S.

Neurobiol Aging. 2009 Feb;30(2):165-73. Epub 2007 Jul 23.

PMID:
17646035

Supplemental Content

Support Center